[Combination of reconstructive vascular operations with gene-engineering technologies of angiogenesis stimulation: a present-day policy aimed at improving the remote results of treating patients with lower limb chronic ischaemia].
The authors have studied therapeutic outcomes in a total of 38 patients diagnosed with occlusions of the femoropopliteal segment. In the Study Group patients (n = 19), the operation of femoropopliteal bypass grafting was supplemented by using gene stimulators of angiogenesis (gene constructions with the genes of vascular endothelial growth factor, and angiogenin). The Control Group patients (n = 19) were subjected to a reconstructive vascular operation alone. The remote results were followed up from six to twenty-six months, having shown reliably better therapeutic outcomes obtained in the Study Group patients, as judged by the distance of pain-free walking, the time of restoration of the baseline parameters of blood flow during the treadmill test, muscular perfusion, and the quality of life indices. A conclusion was made that the use ofangiogenesis-stimulating methods combined with reconstructive vascular operations improves the long-term outcomes in patients presenting with lower limb chronic ischaemia.
A V
AV
Gavrilenko
D A
DA
Voronov
B A
BA
Konstantinov
N P
NP
Bochkov
D000368:Aged; D043925:Angiogenesis Inducing Agents / Q000008:administration & dosage; D001807:Blood Vessel Prosthesis; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005080:Exercise Test; D005260:Female; D005500:Follow-Up Studies; D019983:Guideline Adherence; D006801:Humans; D007273:Injections, Intramuscular; D007511:Ischemia / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D018919:Neovascularization, Physiologic / Q000502:physiology*; D011788:Quality of Life; D012259:Ribonuclease, Pancreatic / Q000008:administration & dosage; D013997:Time Factors; D023822:Tissue Engineering / Q000379:methods*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage; D014656:Vascular Surgical Procedures / Q000379:methods*
D043925:Angiogenesis Inducing Agents; D042461:Vascular Endothelial Growth Factor A; C046366:angiogenin; D012259:Ribonuclease, Pancreatic